Esketamine - Johnson & Johnson

Drug Profile

Esketamine - Johnson & Johnson

Alternative Names: JNJ-54135419; S-ketamine

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Johnson & Johnson
  • Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Major depressive disorder

Most Recent Events

  • 12 Jun 2017 Janssen Research & Development plans a phase II trial for Major depressive disorder (Adjunctive treatment, In adolescents) in USA, Belgium, France, Brazil, Bulgaria, Hungary, Poland and Spain (Intranasal) (NCT03185819)
  • 02 Jun 2017 Janssen plans a phase III trial for Major depressive disorder in USA, Belgium, Canada, Czech Republic, Poland and Turkey (NCT03097133)
  • 05 Apr 2017 Janssen Research and Development completes a phase I safety trial in Healthy volunteers in Germany (Intranasal and IV) (NCT02737605)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top